InVivoMAb anti-human/rat HER2 (neu)

Kodumudi KN, Ramamoorthi G, Snyder C, et al. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. Front Immunol. 2019,10:1939. doi: 10.3389/fimmu.2019.01939

Wang Q, Guldner IH, Golomb SM, et al. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer. Nat Commun. 2019,10(1):3817. doi: 10.1038/s41467-019-11729-1

Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010,18(2):160-70. doi: 10.1016/j.ccr.2010.06.014

Knutson KL, Almand B, Dang Y, et al. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 2004,64(3):1146-51.

Zhang H, Wang Q, Montone KT, et al. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp Mol Pathol. 1999,67(1):15-25.

Drebin JA, Stern DF, Link VC, et al. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature. 1984,312(5994):545-8.

Drebin JA, Link VC, Weinberg RA, et al. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U S A. 1986,83(23):9129-33.